TCGA-38-4627-01A-01R-1206-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 64
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.690
- ANGIOGENESIS+0.510
- COAGULATION+0.460
- HEDGEHOG_SIGNALING+0.420
- MYOGENESIS+0.420
- KRAS_SIGNALING_UP+0.410
- UV_RESPONSE_DN+0.390
- COMPLEMENT+0.380
- INFLAMMATORY_RESPONSE+0.380
- APICAL_JUNCTION+0.360
Top 10 suppressed
- MYC_TARGETS_V2-0.620
- E2F_TARGETS-0.590
- G2M_CHECKPOINT-0.560
- MYC_TARGETS_V1-0.420
- MITOTIC_SPINDLE-0.370
- DNA_REPAIR-0.280
- UNFOLDED_PROTEIN_RESPONSE-0.220
- MTORC1_SIGNALING-0.180
- SPERMATOGENESIS-0.160
- OXIDATIVE_PHOSPHORYLATION-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-46-3766-01A-01R-0980-07 | — | cohortSQ1 | 0.945 |
| 2 | TCGA-44-6777-01A-11R-1858-07 | — | cohortA1 | 0.936 |
| 3 | SRR25617929 | — | A | 0.926 |
| 4 | TCGA-E9-A22E-01A-11R-A157-07 | — | A | 0.925 |
| 5 | TCGA-CR-7386-01A-11R-2016-07 | — | — | 0.924 |
| 6 | ERR2208941 | — | — | 0.923 |
| 7 | MBCProject_0419_T2_RNA | — | A | 0.922 |
| 8 | TCGA-E9-A1NF-01A-11R-A14D-07 | — | C | 0.919 |
| 9 | TCGA-49-6744-01A-11R-1858-07 | — | cohortA1 | 0.916 |
| 10 | TCGA-55-8091-01A-11R-2241-07 | — | cohortA1 | 0.916 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.690 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.510 | Remibrutinib | — uncovered |
| COAGULATION | 0.460 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.420 | Inavolisib | — uncovered |
| MYOGENESIS | 0.420 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.410 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| COMPLEMENT | 0.380 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.360 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.290 | Inavolisib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| APOPTOSIS | 0.260 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.250 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.240 | Inavolisib | — uncovered |